pTSara-NatB, an improved N-terminal acetylation system for recombinant protein expression in *E. coli*

Matteo Rovere, Alex Edward Powers, Dushyant Shailesh Patel, Tim Bartels*

Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

* tbartels@bwh.harvard.edu

Abstract

N-terminal acetylation is one of the most common co- and post-translational modifications of the eukaryotic proteome and regulates numerous aspects of cellular physiology, such as protein folding, localization and turnover. In particular α-synuclein, whose dyshomeostasis has been tied to the pathogenesis of several neurodegenerative disorders, is completely Nα-acetylated in nervous tissue. In this work, building on previous reports, we develop and characterize a bacterial N-terminal acetylation system based on the expression of the yeast N-terminal acetyltransferase B (NatB) complex under the control of the P_{BAD} (L-arabinose-inducible) promoter. We show its functionality and the ability to completely Nα-acetylate our model substrate α-synuclein both upon induction of the construct with L-arabinose and also by only relying on the constitutive expression of the NatB genes.

Introduction

Protein Nα-acetylation, or N-terminal acetylation, is one of the most common co- and post-translational modifications of the eukaryotic proteome, with a vast majority of all N-termini (~80%) bearing this moiety. The reaction is catalyzed by a class of enzymes, N-terminal acetyltransferases (NATs), of which seven (NatA to NatF, and NatH) have to-date been discovered in humans and one (NatG) has been identified in *Arabidopsis thaliana*, with no human ortholog [1,2]. These enzymes mediate the transfer of an acetyl group from acetyl-CoA to the positively charged N-terminus of the protein. Their activity often requires the formation of a complex with the ribosome, mediated by one or two auxiliary, ribosome-anchoring subunits, which provide scaffolding for the catalytic subunit and, in some cases, also regulate its substrate specificity [3,4]. Nα-acetylation thus occurs usually [1,5] in a co-translational fashion, with the acetyl moiety being added to the nascent polypeptide chain [6,7]. Different enzymes of the NAT family will show different specificities for the polypeptidic substrates to be N-terminally acetylated, based on the first 2–4 amino acids of the nascent chain [1]. The role of N-terminal acetylation varies wildly from protein to protein and organism to organism, but it has been shown to be central to protein homeostasis and cellular physiology, regulating protein half-lives, protein-protein interactions, subcellular localization, folding and aggregation [1].
α-synuclein (αSyn) is one of proteins for which the effects of N-terminal acetylation have been shown to be central to its physiology and pathology. αSyn is a small protein (140 aa, 14.6 kDa) ubiquitously and abundantly expressed in nervous tissue [8,9]. While its exact function is still unclear, it has long been associated with the regulation of synaptic activity and neurotransmitter release [8,10]. Most importantly, both genetic and histopathologic evidence have tied it to the pathogenesis of a class of diseases known as synucleinopathies [11], including Parkinson’s Disease, the second most common progressive neurodegenerative disorder [12]. The totality of αSyn in human tissue has been shown to be Nα-acetylated [13,14] and a number of studies have highlighted the role of this modification in the modulation of αSyn’s lipid binding, aggregation, oligomerization and helical propensity [15–18]. This is especially important given the ongoing discussion on the structure of native αSyn in a cellular environment, which requires structural studies to be performed on a species as close as possible to the one present in nervous tissue [19].

αSyn, whose primary sequence begins with MD-, is a substrate of NatB, which acetylates Met-‘Asx/Glx’-type N-termini (MD-, ME-, MN-, and MQ-) [20,21]. NatB is a cytoplasmic, ribosome-associated complex of the Naa20 catalytic subunit (hNAT3, homolog of yeast Nat3p) and the Naa25 auxiliary subunit (hMDM20, homolog of yeast Mdm20p), which serves as a scaffold for Naa20 and mediates ribosome anchoring [4,20,22].

While the expression of recombinant, Nα-acetylated proteins is possible in eukaryotic hosts as yeast and insect cells, a prokaryote-compatible Nα-acetylation system in bacteria (e.g. E. coli) would provide a cheaper and easier-to-use alternative. Although NATs are present in bacteria and archaea the occurrence of N-terminal acetylation is much lower and the NATs’ specificity and regulation are not well-characterized [23]. One approach has been to co-express yeast NATs along with the target protein in bacteria and it has been applied successfully to most of the NATs’ substrates [24,25]. While promising, this method has some shortcomings. The overexpression of both NATs and the target protein under the same inducible promoter does not ensure the proper folding and assembly of the NAT complex before the expression of the Nα-acetylation target begins, which, given the co-translational nature of this modification, can lead to Nα-acetylated/non-Nα-acetylated mixtures [25,26]. We have thus developed an improved Nα-acetylation system, pTSara-NatB, under the control of a PBAD promoter [27] and tested its performance using αSyn as a model substrate.

Materials and methods
Materials
All materials were obtained from Sigma-Aldrich (St. Louis, MO), unless otherwise noted.

Molecular cloning
pTSara was a gift from Matthew Bennett (Addgene plasmid # 60720) [28]. pNatB (pACYC-duet-naa20-naa25) was a gift from Dan Mulvihill (Addgene plasmid # 53613) [24]. Mutagenesis of the pNatB construct to correct the A2520G mutation was performed using the QuikChange II site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA) and primers G2520A FWD 5’-CGTCGTTTGAATGTATGAATCGATCATTCCTTCACCAAC-3’ and G2520A REV 5’-GTTGGTGAAGGAATGATCGATTACATTCAAACGACG-3’; to insert a PvuI restriction site in pTSara, upstream of the T7Te terminator, the primers PvuI FWD 5’-TGTGATCCAAGCCAGCTCGATCGCCGTCGGCTTG-3’ and G2520A REV 5’-GTGGTGAAAGGAATGATCGATTTCCATACATTCAACGACG-3’; to insert a Pvul restriction site in pTSara, upstream of the T7Te terminator, the primers PvuI FWD 5’-TGTGATCCCAAGCCAGCTCGATCGCCGTCGGCTTG-3’ and PvuI REV 5’-CAACGCAGCGGCGATCGATTTCCATTACATTCAACGACG-3’ were used. The Naa20 insert in pNatB
G2520A was PCR-amplified using the primers Naa20 FWD 5’-ATGGCTGATTTGGCAGAATG-3’ and Naa20 REV 5’-ATGCGGCCCTGCGACGTTGAC-3’.
GAAACATCAGCTGG–3’ and inserted into pTSara_PvuI (linearized with SpeI/SalI) using the In-Fusion HD Cloning Kit (Takara Bio, Mountain View, CA). The Naa25 insert in pNatB_G2520A was PCR-amplified using the primers Naa25 FWD 5’–TTTTTTGGGCTAGCGAGGCTCTATTAGATATACATATGCGTCGTTCTGGGA GTAAAGAATC–3’ and Naa25 REV 5’–ATCCAAAGCGAGTCCGATCGCTAAATTCTAAAAATTTGGAAGCTTGCT–3’ and inserted into pTSara_PvuI-Naa20 (linearized with SacI/PvuI) using the In-Fusion HD Cloning Kit (Takara Bio, Mountain View, CA). Cloning of pTSara_PvuI-Naa20-Naa25 (pTSara-NatB) and of all of the cloning intermediates was confirmed by DNA sequencing (Molecular Biology Core Facilities, Dana-Farber Cancer Institute) and restriction analysis.

αSyn expression and purification

pET21a-alpha-synuclein was a gift from the Michael J. Fox Foundation MJFF (Addgene plasmid # 51486). BL21(DE3) E. coli (New England Biolabs, Ipswich, MA) were freshly co-transformed with pET21a-alpha-synuclein and pTSara-NatB and selected on ampicillin- (amp) and chloramphenicol- (cam) supplemented LB-agar plates. Cultures were grown in LB+amp+cam and induced at an OD₆₀₀ of 0.5–0.6 with 0.2% (m/v) L-arabinose and, after 30 min, with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG, or with IPTG alone at an OD₆₀₀ of 0.5–0.6). Growth was continued for 4 hrs. at 37˚C under shaking. The cell pellet, after being harvested and kept frozen at -20˚C overnight, was resuspended in 20 mM Tris buffer, 25 mM NaCl, pH 8.00, and lysed by boiling for 15 min. The supernatant of a 20-min, 20,000 x g spin of the lysate was then further processed. The sample was loaded on two 5-mL (tandem) HiTrap Q HP anion exchange columns (GE Healthcare, Pittsburgh PA), equilibrated with 20 mM Tris buffer, 25 mM NaCl, pH 8.00. αSyn was eluted from the columns with a 25–1000 mM NaCl gradient in 20 mM Tris buffer, 1 M NaCl, pH 8.00. For hydrophobic interaction chromatography αSyn peak fractions were pooled and injected on two 5-mL (tandem) HiTrap Phenyl HP hydrophobic interaction columns (GE Healthcare, Pittsburgh, PA), equilibrated with 50 mM phosphate buffer, 1 M (NH₄)₂SO₄, pH 7.40. αSyn was eluted from the columns with a 1000–0 mM (NH₄)₂SO₄ gradient in Milli-Q water. αSyn peak fractions were then pooled and further purified via size-exclusion chromatography on a HiPrep Sephacryl S-200 HR 26/60 column (GE Healthcare, Pittsburgh, PA) using 50 mM NH₄Ac, pH 7.40 as running buffer. αSyn peak fractions were pooled, aliquoted, lyophilized and stored at -20˚C.

Antibodies

2F12 mouse mAb against human αSyn and Anti-NAT5 mouse mAb against human Naa20 (clone 2C6) were obtained from Sigma-Aldrich (St. Louis, MO) and used, respectively, at 1:10,000 and 1:1000 dilution. Anti-C12orf30 rabbit pAb against human Naa25 was obtained from Abgent (San Diego, CA) and used at a 1:1000 dilution.

SDS-PAGE and immunoblotting

Electrophoresis and blotting reagents were obtained from Thermo Fisher Scientific (Waltham, MA), unless otherwise noted. Samples were prepared for electrophoresis by the addition of 4x NuPAGE LDS sample buffer supplemented with 2.5% β-mercaptoethanol and denatured at 85˚C for 10 min. Samples were electrophoresed on NuPAGE Novex 4–12% Bis-Tris gels with NuPAGE MES-SDS running buffer and using the SeeBlue Plus2 MW marker. Gels were Coo massie Brilliant Blue- (CBB) stained using GelCode Blue Safe Protein Stain, according to the manufacturers’ protocol, and imaged using a LI-COR Odyssey Classic scanner (LI-COR Biosciences, Lincoln, NE). After the electrophoresis, for immunoblotting, gels were electrobotted onto Immobilon-PSQ 0.2 μm PVDF membrane (Millipore, Billerica, MA) for 1 hr. at 400 mA
constant current at 4˚C in 25 mM Tris, 192 mM glycine, 20% (v/v) methanol transfer buffer. After transfer, the membranes of gels run with lysate samples were incubated in 4% (m/v) paraformaldehyde in phosphate buffered saline (PBS) for 30 min at RT, rinsed (3x) 5 min with PBS and blocked with a 5% milk solution (PBS containing 0.1% (v/v) Tween 20 (PBS-T) and 5% (m/v) powdered milk) for either 1 hr. at RT or overnight at 4˚C. After blocking, membranes were incubated in primary antibody in 5% milk solution for either 1 hr. at RT or overnight at 4˚C. Membranes were washed (3x) 5 min in PBS-T at RT and incubated (30 min at RT) in horseradish peroxidase-conjugated secondary antibody (GE Healthcare, Pittsburgh, PA) diluted 1:10,000 in 5% milk solution. Membranes were then washed (3x) 5 min in PBS-T and developed with SuperSignal West Dura according to manufacturers’ instructions.

**Mass spectrometry**

Samples were analyzed on an ABI 4800 TOF/TOF Matrix-Assisted Laser Desorption Ionization (MALDI) mass spectrometer (Applied Biosystems, Foster City, CA). Samples undergoing trypsin digestion were incubated overnight in 50 mM NH₄HCO₃, 5 mM CaCl₂, and 12.5 ng μL⁻¹ of trypsin, then desalted and concentrated using Millipore C18 ZipTips before spotting. Both trypsin-digested samples and samples for intact mass analysis were prepared for spotting by mixing 0.5 μL of sample with 0.5 μL of α-cyano-4-hydroxy-trans-cinnamic acid (10 mg ml⁻¹ in 70% acetonitrile, 0.1% TFA). After drying, samples were rinsed with 0.1% TFA. In addition to external calibration, when measuring intact masses insulin was added as an internal standard, for higher accuracy.

**Growth curves**

Colonies of either singly transformed (pET21a-alpha-synuclein) or co-transformed (pET21a-alpha-synuclein+pTSara-Nat B) BL21(DE3) E. coli (New England Biolabs, Ipswich, MA) were picked from fresh (<2 weeks) agar-LB+amp or agar-LB+amp+cam plates and inoculated in LB+amp or LB+amp+cam. After 8–10 hrs. of growth, at 37˚C under shaking, the cultures, then in their stationary phase, were diluted 1:30 in fresh medium+antibiotic (and 0.2% L-arabinose in one case), aliquoted in 96-well clear sterile plastic plates, sealed with gas-permeable sealing membranes and grown at 37˚C under shaking overnight. Absorbance (optical density) at 600 nm (OD₆₀₀) was measured every 15 min with a Synergy H1 microplate reader (BioTek, Winooski, VT). Data were analyzed with GraphPad Prism 7 (GraphPad Software, La Jolla, CA).

**Results**

In uncoupling the induction of the NatB complex and αSyn (or any of NatB’s substrates) two courses of action are possible: either changing the operon regulating the transcription of the NatB genes or the one acting on the SNCA (αSyn) gene. While the authors of the original NatB work suggest [26] and recently implemented [25] an N-terminal acetylation system where the target protein is under a rhamnose-inducible promoter, we decided to redesign pNatB into an arabinose-inducible system. This approach provides two clear advantages. First, using a promoter weaker than the T7/lac of the PET system will dramatically decrease the protein yield (one of the reasons for employing a bacterial expression system in the first place). In addition, the function of the N-terminal acetylation complex can be performed by catalytic amounts of enzyme and, as such, low expression levels should be more than sufficient for the complete modification of the target and, at the same time, pose less of a metabolic burden to the cells. Following the original approach used for pNatB and starting from the bicistronic construct pTSara [28], we cloned both the catalytic, Naa20, and regulatory, Naa25, subunit
into pTSara, maintaining the ribosome-binding region of pACYC-Duet-1 (a previously reported missense A-to-G mutation in the Naa25 gene [29] was also corrected), (Fig 1A) and called the construct pTSara-NatB. We then verified the success of the expression by CBB-stained SDS-PAGE and immunoblotting of Naa20 and Naa25 (Fig 1B and 1C). In addition, we tested the compatibility of pTSara-NatB with the SNCA expression vector (pET21a-alpha-synuclein) by co-transforming and inducing doubly-selected cells containing both plasmids.

Fig 1. Molecular cloning and characterization of pTSara-NatB. (A) Plasmid map and cloning strategy of pTSara-NatB. (B) CBB-stained SDS-PAGE of pTSara-NatB-transformed E. coli (PBS-soluble) lysates before and after (2, 4 hrs.) induction with 0.2% L-arabinose. Bands corresponding to the regulatory (Naa25) and catalytic (Naa20) subunits of the NatB complex are marked. (C) Western blots of pTSara-NatB-transformed E. coli lysates before and after (2, 4 hrs.) induction with 0.2% L-arabinose before and after induction with 0.2% L-arabinose. Antibodies to the human homologs of the yeast NatB components were used for detection (top Naa25, Anti-C12orf30 1:1000; bottom Naa20, Anti-NAT5 1:1000). Non-marked bands are cross-reactive E. coli proteins. (D, top) CBB-stained SDS-PAGE of pET-alpha-synuclein+pTSara-NatB co-transformed E. coli lysates before 0.2% L-arabinose induction (before ara) or 1 mM IPTG induction (before IPTG, added 30 min after L-arabinose) and 2 hrs. after IPTG induction. Both subunits of the NatB complex and αSyn are marked. (D, bottom) αSyn Western blot of co-transformed E. coli lysates, in order to confirm the absence of any cross-reactivity between L-arabinose and IPTG induction, 2F12 (1:10,000) was used for αSyn detection.

https://doi.org/10.1371/journal.pone.0198715.g001
0.2% of L-arabinose, which has been shown to promote a robust expression of \( P_{BAD} \)-regulated genes [27], was used for the induction of the \( ara \) operon. L-arabinose was added upon reach of a culture density (OD\(_{600}\)) of about 0.5, 30 min before the addition of IPTG for pET induction. Both the expression of the NatB subunits and that of the target protein appear to be unaffected by the co-expression and there is no evidence of cross-talk (e.g. \( \alpha \)Syn expression upon arabinose addition) between the operons (Fig 1D).

The N-terminal acetylation efficiency of pTSara-NatB was then tested, using \( \alpha \)Syn as a substrate, with the same protocol described before for double transformation and sequential induction. Matrix-Assisted Laser Desorption Ionization-Time Of Flight (MALDI-TOF) Mass Spectrometry (MS) of the purified protein from BL21(DE3) \( E. coli \) co-transformed with pTSara-NatB and pET21a-\( \alpha \)-synuclein, either induced or non-induced with L-arabinose, shows, somewhat surprisingly, complete substrate N\( ^{\alpha} \)-acetylation in both cases (Fig 2). However, these results can be easily explained by the fact that complete silencing of the \( ara \) operon is not attainable by simple absence of the inducer. The catalytic nature of the NatB complex ensures that even small amounts, constitutively expressed, can acetylate efficiently the totality of the target protein. Confirming this mechanistic explanation, addition of D-glucose (0.2%) to the bacterial cultures, which has been shown to reduce the level of non-induced expression of \( P_{BAD} \)-regulated genes through catabolite repression [27,30], reduced the fraction of N\( ^{\alpha} \)-acetylated \( \alpha \)Syn to about 50% (S1 Fig). We also found that such mixtures of N\( ^{\alpha} \)-acetylated and non-N\( ^{\alpha} \)-acetylated \( \alpha \)Syn can be resolved by hydrophobic interaction chromatography (S2 Fig).

pTSara-NatB thus works as a low-level constitutive expression vector and can potentially be L-arabinose-regulated in the case of difficult substrates (see, e.g., [24]).

![MALDI-TOF MS analysis of the N-terminal acetylation efficiency of pTSara-NatB](https://doi.org/10.1371/journal.pone.0198715.g002)
Fig 3. MALDI-TOF MS of trypsin-digested αSyn. MALDI-TOF mass spectra of trypsin-digested samples of αSyn purified from E. coli transformed with pET21a-α-synuclein alone (A) or pET21a-α-synuclein+pTSara-NatB (B) and only induced with 1 mM IPTG (see Table 1). The ~42 Da shift in the N-terminal fragment (770.43 Da → 812.45 Da) confirms the successful and complete N-terminal acetylation of αSyn upon NatB co-expression.

https://doi.org/10.1371/journal.pone.0198715.g003
Since MALDI-TOF MS could mask the presence of a small population of non-N-terminal-acetylated substrate, trypsin digestion followed by MALDI-TOF MS was also performed on a control (non-N-terminal-acetylated) sample and one of purified αSyn from non-L-arabinose-induced co-transformed E. coli (100% N-terminal-acetylated according to MALDI-TOF MS). The mass spectrum of the fragments (Fig 3 and Table 1) confirms the N-terminal +42 Da mass shift that corresponds to N-terminal acetylation and the efficiency of the co-translational modification (>97%).

Finally, especially given the constitutive expression of our construct, the effects of widespread N-terminal acetylation on the bacterial proteome (and in particular its potential toxicity or metabolic modulation) were tested comparing the growth curves of BL21(DE3) transformed with either pET21a-alpha-synuclein alone or pET21a-alpha-synuclein+pTSara-NatB (with or without L-arabinose induction) (Fig 4). Both in non-L-arabinose-induced (pET+) and induced (pET+pTSara+0.2% ara) co-transformed E. coli there is an increase in the OD$_{600}$ of the cultures, when compared to those of singly transformed bacteria (pET). No toxicity is thus observed, rather an increased bacterial proliferation (although the kinetics of the growth do not appear to be changed by the introduction of N-terminal acetylation), the reason of which has not been yet investigated. It must be noted how such increased culture density does not reflect in increased yields of N-terminal-acetylated αSyn (in contrast with what previously reported for other NatB substrates [24]).

### Discussion

In this work we developed and characterized pTSara-NatB, an improved N-terminal acetylation construct for recombinant protein expression in E. coli. We tested its ability to completely N-terminal-acetylate our (model) target protein αSyn both upon L-arabinose induction and by relying only on the uninduced constitutive expression of the NatB complex subunits.

A clear advantage of the pTSara-NatB-mediated N-terminal acetylation is the ease with which the uninduced, constitutive expression of NatB ensures. Viable substrates can be completely acetylated merely by the presence of the construct in co-transformed bacteria. In addition, the L-arabinose-inducible system (possibly in combination with a rhamnose-controlled expression vector in the case of problematic targets [25]) provides a flexibility that should secure the

**Table 1. Identity of the most abundant peptide fragments identified in the MALDI-TOF mass spectra of trypsin-digested αSyn [31].**

| Mass          | Position | #MC | Peptide Sequence                  |
|---------------|----------|-----|-----------------------------------|
| 2157.1873     | 59–80    | 1   | TKEQVTNVGAAGGGVGTAVARRQ         |
| 1928.0447     | 61–80    | 0   | EQVTNVGAAGGGVGTAVARRQ         |
| 1606.8798     | 81–97    | 1   | TVEGASIAAATGFVK                |
| 1524.8380     | 44–58    | 1   | TKEGQVQGATVAAK                |
| 1524.8380     | 46–60    | 1   | EGQHGVATVAAE                 |
| 1478.7849     | 81–96    | 0   | TVEGASIAAATGFVK                |
| 1295.6953     | 46–58    | 0   | EGQHGVATVAAE                 |
| 1180.6572     | 33–43    | 1   | TKEGQLYGSK                   |
| 1180.6572     | 35–45    | 1   | EGQLYGSK                    |
| 1072.5996     | 11–21    | 1   | AKEGQVAAAE                 |
| 951.5145      | 35–43    | 0   | EGQLYGSK                   |
| 812.3948      | 1–6      | 0   | Ac-MDVFMK                    |
| 770.3575      | 1–6      | 0   | MDVFDMK                    |

*Missed Cleavages.*

https://doi.org/10.1371/journal.pone.00198715.t001
complete N-terminal acetylation of even intractable substrates. In addition, all our testing was done in LB medium and showed excellent N-α-acetylation efficiency (pNatB has been reported to perform best in rich culture media, such as NZY [26]), which could possibly extend its use to minimal medium, as in the expression of isotopically-labeled recombinant proteins. We also observed, as previously reported [26], how N-terminal acetylation is complete only in freshly transformed E. coli.

Future developments should be the cloning of similar constructs for the other members of the NAT family [25], so to allow the recombinant expression of the whole N-terminal acetylome in bacteria, and extensive testing on a variety of substrates and culture conditions.

Supporting information

S1 Fig. MALDI-TOF MS analysis of the N-terminal acetylation efficiency of pTSara-NatB in the presence of 0.2% D-glucose. MALDI-TOF mass spectrum of αSyn purified from E. coli
transformed with pET21a-alpha-synuclein+pTSara-NatB, grown in the presence of 0.2% D-glucose and induced with 1 mM IPTG (predicted MW of Nα-acetylated αSyn 14502.20 Da).

S2 Fig. Hydrophobic interaction chromatography (HIC) can resolve Nα-acetylated and non-Nα-acetylated αSyn mixtures. (A) MALDI-TOF mass spectrum of αSyn purified from E. coli transformed with pET21a-alpha-synuclein+pNatB and induced with 1 mM IPTG, showing a mixture of Nα-acetylated and non-Nα-acetylated αSyn. (B) Chromatogram of the HIC elution step of an aliquot from the same expression batch (in blue the 280-nm UV absorbance, in red the conductivity). HIC resolves Nα-acetylated and non-Nα-acetylated mixtures of αSyn (Nα-acetylated αSyn has a slightly higher retention volume), as confirmed by MALDI-TOF MS on the two αSyn peaks, after size-exclusion chromatography (non-Nα-acetylated αSyn, C; Nα-acetylated αSyn, D).

S3 Fig. Uncropped Western blots.

Acknowledgments

We thank Zach Herbert, Jim Lee and the Molecular Biology Core Facilities of the Dana-Farber Cancer Institute for the use of instruments and assistance with Sanger DNA sequencing and mass spectrometry. We also thank our colleagues at the Ann Romney Center for Neurologic Diseases for many helpful discussions.

Author Contributions

Conceptualization: Tim Bartels.

Data curation: Matteo Rovere, Alex Edward Powers, Dushyant Shailesh Patel.

Formal analysis: Matteo Rovere, Alex Edward Powers, Dushyant Shailesh Patel, Tim Bartels.

Investigation: Matteo Rovere, Alex Edward Powers, Dushyant Shailesh Patel, Tim Bartels.

Supervision: Tim Bartels.

Writing – original draft: Matteo Rovere, Tim Bartels.

Writing – review & editing: Alex Edward Powers, Dushyant Shailesh Patel.

References

1. Aksnes H, Drazic A, Marie M, Arnesen T. First Things First: Vital Protein Marks by N-Terminal Acetyltransferases. Trends Biochem Sci. 2016; 41: 746–760. https://doi.org/10.1016/j.tibs.2016.07.005 PMID: 27498224

2. Drazic A, Aksnes H, Marie M, Boczkowska M, Varland S, Timmerman E, et al. NAA80 is actin’s N-terminal acetyltransferase and regulates cytoskeleton assembly and cell motility. Proc Natl Acad Sci U S A. 2018; 115: 4399–4404. https://doi.org/10.1073/pnas.1718336115 PMID: 29581253

3. Liszczak G, Goldberg JM, Foyn H, Petersson EJ, Arnesen T, Marmorstein R. Molecular basis for N-terminal acetylation by the heterodimeric NatA complex. Nat Struct Mol Biol. 2013; 20: 1098–1105. https://doi.org/10.1038/nsmb.2636 PMID: 23912279

4. Hong H, Cai Y, Zhang S, Ding H, Wang H, Han A. Molecular Basis of Substrate Specific Acetylation by N-Terminal Acetyltransferase NatB. Structure. Elsevier Ltd.; 2017; 25: 641–649.e3. https://doi.org/10.1016/j.str.2017.03.003 PMID: 28380339

5. Van Damme P, Evjenth R, Foyn H, Demeyer K, De Bock P-J, Lillehaug JR, et al. Proteome-derived Peptide Libraries Allow Detailed Analysis of the Substrate Specificities of N(alpha)-acetyltransferases
and Point to hNaa10p as the Post-translational Actin N(alpha)-acetyltransferase. Mol Cell Proteomics. 2011; 10: M110.004580. https://doi.org/10.1074/mcp.M110.004580 PMID: 21383206

6. Gautschi M, Just S, Mun A, Ross S, Rücknagel P, Dubaqué Y, et al. The yeast N(alpha)-acetyltransferase NatA is quantitatively anchored to the ribosome and interacts with nascent polypeptides. Mol Cell Biol. 2003; 23: 7403–14. https://doi.org/10.1128/MCB.23.20.7403-7414.2003 PMID: 14517307

7. Polevoda B, Brown S, Cardillo TS, Rigby S, Sherman F. Yeast N(alpha)-terminal acetyltransferases are associated with ribosomes. J Cell Biochem. 2008; 103: 492–500. https://doi.org/10.1002/jcb.21418 PMID: 17541948

8. Bendor JT, Logan TP, Edwards RH. The function of α-synuclein. Neuron. Elsevier Inc.; 2013; 79: 1044–66. https://doi.org/10.1016/j.neuron.2013.09.004 PMID: 24050397

9. Iwai A, Masiah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, et al. The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995; 14: 467–75. https://doi.org/10.1016/0896-6273(95)90302-X PMID: 7857654

10. Lautenschläger J, Kaminski CF, Kaminski Schierle GS. α-Synuclein—Regulator of Exocytosis, Endocytosis, or Both? Trends Cell Biol. 2017; 27: 468–479. https://doi.org/10.1016/j.tcb.2017.02.002 PMID: 28259601

11. Shulman JM, De Jager PL, Feany MB. Parkinson’s disease: genetics and pathogenesis. Annu Rev Chem. 2016; 291: 21110–21122. https://doi.org/10.1074/jbc.M116.726612 PMID: 27531743

12. de Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006; 5: 525–35. https://doi.org/10.1016/S1474-4422(06)70747-9 PMID: 16713924

13. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello Rj, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006; 281: 29739–52. https://doi.org/10.1074/jbc.M600933200 PMID: 16847063

14. Bartels T, Choi JG, Selkoe DJ. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011; 477: 107–10. https://doi.org/10.1038/nature10324 PMID: 21841800

15. Traxler AJ, Rhoades E. N-Terminal acetylation is critical for forming α-helical oligomers of α-synuclein. Protein Sci. 2012; 21: 601–5. https://doi.org/10.1002/pro.2056 PMID: 22407793

16. Dikiy I, Eliezer D. N-terminal acetylation stabilizes N-terminal helicity in lipid- and micelle-bound α-synuclein and increases its affinity for physiological membranes. J Biol Chem. 2014; 289: 3652–65. https://doi.org/10.1074/jbc.M113.512459 PMID: 24338013

17. Bartels T, Kim NC, Luth ES, Selkoe DJ. N-alpha-acetylation of α-synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation. PLoS One. 2014; 9: 1–10. https://doi.org/10.1371/journal.pone.0103727 PMID: 25075858

18. Iyer A, Roeters SJ, Schilderink N, Hommersom B, Heeren RMA, Woutersen S, et al. The Impact of N-terminal Acetylation of α-Synuclein on Phospholipid Membrane Binding and Fibril Structure. J Biol Chem. 2016; 291: 21110–21112. https://doi.org/10.1074/jbc.M116.726612 PMID: 27531743

19. Selkoe D, Dettmer U, Luth E, Kim N, Newman A, Bartels T. Defining the native state of α-synuclein. Neurodegener Dis. 2014; 13: 114–117. https://doi.org/10.1159/000355516 PMID: 24192542

20. Starheim KK, Arnesen T, Gromyko D, Ryningen A, Varhaug JE, Lillehaug JR. Identification of the human N(alpha)-acetyltransferase complex B (hNatB): a complex important for cell-cycle progression. Biochem J. 2006; 415: 325–31. https://doi.org/10.1042/BJ20060658 PMID: 18570629

21. Van Damme P, Lasa M, Polevoda B, Gazquez C, Elsoegui-Artola A, Kim DS, et al. N-terminal acetylation analyses and functional insights of the N-terminal acetyltransferase NatB. Proc Natl Acad Sci U S A. 2012; 109: 12449–54. https://doi.org/10.1073/pnas.120303109 PMID: 22814378

22. Polevoda B, Cardillo TS, Doyle TC, Bedi GS, Sherman F. Nat3p and Mdm20p are required for function of yeast NatB Nalpha-terminal acetyltransferase and of actin and tropomyosin. J Biol Chem. 2003; 278: 30686–97. https://doi.org/10.1074/jbc.M304690200 PMID: 12783868

23. Jones JD, O’Connor CD. Protein acetylation in prokaryotes. Proteomics. 2011; 11: 3012–22. https://doi.org/10.1002/pmc.201000812 PMID: 21674803

24. Johnson M, Coulton AT, Geeves M a., Mulvihill DP. Targeted amino-terminal acetylation of recombinant proteins in E. coli. PLoS One. 2010; 5: e15801. https://doi.org/10.1371/journal.pone.0015801 PMID: 21203426

25. Eastwood T, Baker K, Brooker H, Frank S, Mulvihill DP. An enhanced recombinant amino-terminal acetylation system and novel in vivo high-throughput screen for molecules affecting α-synuclein oligomerization. FEBS Lett. 2017; 38: 42–49. https://doi.org/10.1002/1873-2468.12937 PMID: 28214355

26. Johnson M, Geeves MA, Mulvihill DP. Production of amino-terminal acetylated recombinant proteins in E. coli. Methods Mol Biol. 2013; 981: 193–200. https://doi.org/10.1007/978-1-62703-305-3_15 PMID: 23381863
27. Guzman LM, Belin D, Carson MJ, Beckwith J. Tight regulation, modulation, and high-level expression by vectors containing the arabinose P(BAD) promoter. J Bacteriol. 1995; 177: 4121–4130. PMID: 7608087

28. Shis DL, Bennett MR. Library of synthetic transcriptional AND gates built with split T7 RNA polymerase mutants. Proc Natl Acad Sci U S A. 2013; 110: 5028–33. https://doi.org/10.1073/pnas.1220157110 PMID: 23479654

29. Addgene: pNatB (pACYCduet-naa20-naa25) [Internet]. [cited 7 May 2018]. https://www.addgene.org/53613/

30. Schleif R. AraC protein, regulation of the L-arabino operon in Escherichia coli, and the light switch mechanism of AraC action. FEMS Microbiol Rev. 2010; 34: 779–96. https://doi.org/10.1111/j.1574-6976.2010.00226.x PMID: 20491933

31. Wilkins MR, Lindskog I, Gasteiger E, Bairoch A, Sanchez JC, Hochstrasser DF, et al. Detailed peptide characterization using PEPTIDEMASS—a World-Wide-Web-accessible tool. Electrophoresis. 1997; 18: 403–8. https://doi.org/10.1002/elps.1150180314 PMID: 9150918